Fabry's Disease Clinical Trial
— SHORTENOfficial title:
A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion
This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.
Status | Recruiting |
Enrollment | 18 |
Est. completion date | October 6, 2025 |
Est. primary completion date | October 6, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 65 Years |
Eligibility | Inclusion Criteria: - Participants with confirmed diagnosis of FD who are =2 and =65 years of age at the time of signing the informed consent form (ICF) or assent, if applicable. - Cohort 1: female participants with body weight =30 kg who have been treated with Fabrazyme for at least 3 months without IARs during the most recent 3 infusions. - Cohort 2: non-classic male participants with body weight =30 kg who have been treated with Fabrazyme for at least 3 months without IARs during the most recent 3 infusions. - Cohort 3: classic male participants with body weight =30 kg who have been treated with Fabrazyme for at least 3 months without IARs during the most recent 3 infusions. - Cohort 4: participants with body weight <30 kg who have been treated with Fabrazyme for at least 3 months without IARs during the most recent 3 infusions. - Cohort 5: ERT-naïve participants. Women of childbearing potential must use a highly effective method of contraception through the study. Exclusion Criteria: - Female participants who are pregnant or breastfeeding. - History of significant allergic disease or hypersensitivity to Fabrazyme or other medicinal products. - Contraindication to Fabrazyme or any of the premedications or rescue medications (diphenhydramine, acetaminophen, montelukast, dexamethasone). - Any other medical condition considered to make the increased infusion rate not tolerable at the Investigator's discretion. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial. |
Country | Name | City | State |
---|---|---|---|
United States | Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 1002 | Fairfax | Virginia |
United States | Infusion Associates Site Number : 1001 | Grand Rapids | Michigan |
United States | Metropolitan Hospital Center Site Number : 1004 | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Sanofi |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction of infusion duration from pretrial average of recent 3 infusions | Baseline to month 4 | ||
Primary | Reduction of infusion duration from initial 120 minutes | Baseline to month 4 | ||
Primary | Shortest infusion duration each participant tolerates | Baseline to month 4 | ||
Secondary | Number of participants achieving the shortest planned duration of infusion time | Baseline to month 4 | ||
Secondary | Percentage of participants achieving the shortest planned duration of infusion time | Baseline to month 4 | ||
Secondary | Number of participants achieving infusion duration shorter than 90 minutes without experiencing any or the second IAR | Baseline to month 4 | ||
Secondary | Percentage of participants achieving infusion duration shorter than 90 minutes without experiencing any or the second IAR | Baseline to month 4 | ||
Secondary | Number of participants achieving infusion duration without experiencing any IAR | Baseline to month 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01178164 -
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains
|
N/A | |
Terminated |
NCT02582294 -
Fabry's Disease and Pregnancy (PREFAB)
|
||
Recruiting |
NCT02469181 -
Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy (RECAFTURE Trial)
|
||
Completed |
NCT02798458 -
Evaluation of the Gastrointestinal Manifestation of Fabry's Disease
|
N/A | |
Completed |
NCT00001491 -
Analysis of the Nervous System in Patients With Fabry's Disease
|
N/A | |
Completed |
NCT02450604 -
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain
|
N/A | |
Recruiting |
NCT04847713 -
Early Detection and Follow-Up of Patients With Fabry's Disease
|